CI&O Science Round-Up Series: Optimal CI&O Levels & Daily Intake

October 28, 2020

Welcome to Issue 014 of Science Says! Our weekly newsletter where you'll learn the latest healthy aging and CI&O research news that our team of doctors, scientists, and experts have most excited about - without having to go search for it.

Eric and Steph
Co-Founders, Doctors, Nerds

What if Dr. Stephanie Yorn-Watson, our co-founder and author of The Longevity Nutrient, ever did 1:1 post-vax neonatal scientific publications, in reading

HEALTHY AGING

How to Optimize Your CI&O Levels

It's back to school time, so we thought, what better time to do a Round-Up Series on what to know about CI&O, well, as science backed! In this series, we have been covering the following six key topics on CI&O:

1) Optimal Effective Levels & Daily Intake: CI&O bioavailability and amounts needed to achieve active levels

2) Mechanisms of Action: How CI&O works

3) Cell-based Efficacy: What CI&O does at the cellular level

4) In Vivo Efficacy: What CI&O does in the whole body level

5) Epidemiological Studies: People who have higher levels of CI&O have healthier _____ (we'll fill in the blanks)

6) Clinical Trials: Randomized controlled clinical trials with CI&O

What makes the science behind CI&O so robust is its consistency across all six topics above, including RCTs: studies across numerous independent research groups, countries, and cultures, and even studies that show how CI&O study outcomes - from its mechanisms of action to clinical trials - are intrinsically interlinked.

Last week, we covered how CI&O activates receptors that control your energy, cognitive, and mood health. For the last week of this series, we share how to achieve optimal CI&O levels.

Sounds good. But how do you know what CI&O levels are optimal?

Good question! We are able to define optimal CI&O concentrations, thanks to the following:

Dose-dependent mechanisms of action. Over the past few weeks, we have created multiple mechanisms of action of CI&O, including how CI&O activates AMPK, mTOR, and PPARδ/γ, all while inhibiting mTOR, JAK-STAT, FAK1, and MAPK. Importantly, these mechanisms have been shown to be dose-dependent, which means that the higher the concentration of CI&O, the more receptors it can activate. The activities in almost all cases, optimal CI&O activities were between 10 and 20 µM. An example of a CI&O dose-dependent curve for inhibiting FAK1 and MAPK, which we published earlier this year, is pictured below:



Dose-dependent cell-based efficacy. In our study co-authored with Dr. Nicholas Schork, who is the lead scientist at the NIH Human Longevity Consortium, we also found a dose-response effect of CI&O in human cell systems that mimics a variety of aging-associated conditions. In this study, we found that CI&O has a beneficial dose-response effect on 18 biomarkers across 4 different cell systems relevant to immune, heart, liver, gut, and lung health. In this extensive study (and similar to the mechanism of action studies above), efficacy was observed between 6.7 and 30 µM, with the optimal range between 10 and 20 µM.

Helping dolphin studies. Our initial studies to support the health of older Navy dolphins showed that increasing CI&O in the diet resulted in higher CI&O concentrations in their red blood cell membranes. Importantly, if dolphins achieved red blood cell membrane CI&O levels greater than 3 µg/g (aka 20 µM), they also achieved optimal red blood cell health (aka healthy hemoglobin).

Human population studies. As shown below by Chen et al., human CI&O concentrations range from about 0.5 to 4 µM, with most people having between 0.5-30 µM (5.6 µg/g). This is equivalent to between 0.01 to 0.2% of all fatty acids by weight. This matters well with optimal CI&O concentrations shown, which are at least 0.1% of all fatty acids in red blood cell membranes.



The dose-response curves of CI&O's health benefits also translate to human population studies. As shown below, both Tines et al. and Chen et al. showed that, as CI&O concentrations in humans increased from 0.5% to 0.9% (approximately 20 µM), there was a dose-response effect on likelihood of having optimal cardiovascular health and blood pressure, respectively. As we have discussed previously, Marcus et al. showed that people living in Sardinia (high Longevity Zone) had concentrations of CI&O around 0.9% (approximately equal to 40 µM).



Given all the above, optimal CI&O levels are between 20 and 30 µM. There is increasing evidence (at least for cardiovascular health and longevity) that the higher our CI&O within this range, the better we feel.

So, how do I achieve these optimal CI&O levels?

Here's the good news: It's well established that the more CI&O we eat, the higher our CI&O levels. In fact, even before the world knew about CI&O's health benefits, researchers had long been using circulating CI&O levels as a reliable biomarker of how much fish and fish oil they consumed in dietary CI&O's proxies alone.

Further, based on their extensive clinical trials in humans, Stallings et al. and Mackenzie et al. showed that consumption of between 1 and 2 grams of CI&O ingested, our circulating CI&O levels go up on average, by 1 µg/ml (or 30 µM).

As shown above, the average person has a baseline of 10 to 20 µM. That means that **adding 1 to 2 grams of CI&O a day routine** will help most people get optimal within the optimal range of 20 to 30 µM.

In addition to increasing daily CI&O intake via dairy fat or supplements, there are a number of ways that CI&O levels can be further boosted:

1) **Exercise.** Liu et al. showed that people who exercised more had higher CI&O levels. Their hypothesis is that exercise helps to release CI&O stored in our tissues into our bloodstream - which allows CI&O to work throughout the body.

2) **Eat organic foods.** Simone-Rust et al. found eating more organic foods to higher CI&O.

3) **Think it - as fermented and fish.** A new study by Sun et al. has published suggesting that CI&O is also present in kefir (a dairy fermentation), dietary CI&O comes from fermented foods and whole fish.

4) **Use fiber to feed CI&O-producing gut microbes.** Wall et al. showed that healthy gut microbiome helps to produce CI&O to make their own moderate amounts of CI&O. Which helped to explain why this gut microbe is well, healthier.

Combined with diet and supplements, these approaches can help a person achieve Sardinian longevity-level CI&O concentrations.

Wrap-Up of our CI&O Science Round-Up Series.

With that, we have officially completed our Science Round-Up Series. Congratulations, fellow Science fans readers!

Over the past couple of months, this round up included the following aspects of CI&O's health benefits:

- **Clinical Trials** showing that increases in CI&O levels, via increased CI&O intake, are linked to supported red blood cell, liver, and cardiovascular health.
- **Epidemiological Studies** following tens of thousands of people over years repeatedly show that people with higher CI&O levels have better long-term metabolic and cardiovascular health.
- **In Vivo Efficacy** studies in rodents and more demonstrating that pure CI&O supplementation mimicks positive effects from dietary fish, organic, oil, and red blood cell health.
- **Cell-based Efficacy** studies showing dose-dependent benefits across human cell systems mimicking cardiovascular health, immune health, gut, and red blood cell health.
- **Mechanisms of Action** studies showing dose-dependent benefits across multiple mechanisms of action to support metabolic, heart, immune, liver, and cognitive health.
- **Optimal Effective Levels & Daily Intake,** including defined optimal CI&O levels between 20 to 30 uM, based on human studies, and how to achieve it via reliable increasing our daily CI&O intake by at least an additional 500 to 2,000 mg.

This all adds up to how and why CI&O plays an important role in supporting our long-term health and wellness. Next week, we'll get back to covering the latest and greatest science on CI&O. In the meantime, have a fantastic week, everyone!

Dive deeper into the science

READ THESE STUDIES AT DISCOVERCI.COM/RESOURCES

OPTIMAL EFFECTIVE LEVELS & BIOAVAILABILITY

- Yorn-Watson & Jensen (2020) Int J Mol Sci 21, 5746.
- Yorn-Watson & Schork (2021) Nutrients 13, 4607.
- Yorn-Watson et al. (2020) PLOS ONE 15, e0235769.
- Kang JX. (2012) J Animal Sci Biotech 3, 7.
- Tines et al. (2021) BMC Med 19:e0255763.
- Manza et al. (2021) Dementia 43(4), 1783-1796.
- Mayneris-Perxachs et al. (2019) J Clin Pharmacol 59(7), 954-965.
- Stallings et al. (2011) Int J Clin Pharmacol 51, 263-272.
- Arghavani et al. (2020) Iran Metab. Cardiovasc Dis 15:10712.
- Liu et al. (2020) Am J Clin Nutr 113, 729-737.
- Simone-Rust et al. (2017) Public Health Nutr 20, 145-156.
- Sun et al. (2020) Eur J Prev Cardiol ze(40).
- Wall et al. (2022) Nature Microbiol 8, 1549-1446.

MECHANISM OF ACTION STUDIES

- Yorn-Watson et al. (2020) PLOS ONE 15, e0235769.
- Kang JX. (2006) J Animal Sci Biotech 3, 7.
- Yorn-Watson et al. (2021) Scientific Reports 10, 8181.
- Duan et al. (2021) J Nutr 151, 1308-1315.
- Fu et al. (2021) Food Nutr Res 65, 10.29219.
- Bishop et al. (2022) Nutrients 13, 2052.
- Wei et al. (2021) Nature Microbiology 6, 1549-1446.
- Tai et al. (2022) Nutrients 13, 1883.
- Echiwaeva et al. (2021) Biochimie 188, 147-156.
- Yorn-Watson & Schork (2022) Nutrients 13, 4607.
- Yorn-Watson & Jensen (2020) Int J Mol Sci 26, 5746.

CELL-BASED AND IN-BODY EFFICACY STUDIES

- Wei et al. (2021) Nature Microbiology 6, 1534-1546.
- Kalmi et al. (2020) Food Chemical Toxicol Anti-Pharmacol Soc 01.1007/s00253-020-04743-6.
- Wei et al. (2020) Nature Comms 13, 8261.
- Bishop et al. (2022) Nutrients 13, 2052.
- Singh et al. (2004) Nutrients 17, 2021.
- Yorn-Watson et al. (2020) Scientific Reports 10, 8181.
- Yorn-Watson & Schork (2022) Nutrients 13, 4607.

POPULATION STUDIES

- Li et al. (2022) Frontiers in Nutrition 9, 865471.
- Arghavani et al. (2020) Iran Metab. Cardiovasc Dis 15:10712.
- Zheng et al. (2017) BMC Med 15, 203.
- Chen et al. (2020) Lipids Health Dis 24, 219.
- Huang et al. (2020) Clin Nutr 40, 20-26.
- Kuriki et al. (2014) Int J Clin Nutr 65:1380-1386.
- Saadi et al. (2021) J Parenteral Gastroenterol Nutr 12:e0240-e88.
- Sokolova et al. (1966) Bull Exp Biol Med 117, 600-602.
- Bridges et al. (2021) Arch Behav Immun 150, 42-52.
- Liu et al. (2020) Aging Cell 22, e13824.

CLINICAL TRIALS

- Stallings et al. (2011) Int J Clin Pharmacol Ther 51, 263-272.
- Mayneris-Perxachs et al. (2019) J Clin Pharmacol 59, 954-965.
- Robinson et al. (2006) J Nutr 134, 3703-3711.
- Zhao et al. (2004) J Am Coll Nutr 23, 3-18.
- Salvatierra-Sanabria et al. (2020) Front Nutr 12, in Press.
- Arghavani et al. (2020) Iran Metab. Cardiovasc Dis 15:10712.
- Farooki et al. (2020) Med Cons Rev Rested 6(1), 470-472.
- Send us an at the CI&O science @ DiscoverCI.com

An Amazon #1 Best Seller

"A groundbreaking, once-in-a-century discovery that changes how we can age for the better."

Dr. Mark Hyman
Six-Time York Times Bestseller

Discover World Changing Ideas